Skip to main content

VERU INC.

corporate_fare Company Profile

VERU INC.

VERU·NASDAQ·Life Sciences·CIK 0000863894

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. The company's drug development program includes two late-stage new chemical entities: enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator ("SARM") designed to make weight reduction by GLP-1 RA drugs more tissue selective for fat loss and lean mass preservation, aiming for improved body composition, physical function, and clinically meaningful incremental weight reduction compared to GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for treating inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, Veru sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), which provided dual protection against unplanned pregnancy and sexually transmitted infections. Veru is a Wisconsin corporation, originally incorporated in 1971 as The Wisconsin Pharmacal Company, Inc. In 1996, the company acquired worldwide rights to its first-generation female condom, divested other businesses, and changed its name to "The Female Health Company." On October 31, 2016, the acquisition of Aspen Park Pharmaceuticals, Inc. ("APP Acquisition") transitioned the company from a single-product company selling FC2 to a biopharmaceutical company with a drug development program. On July 31, 2017, the corporate name changed to "Veru Inc." On August 8, 2025, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock.

VERU INC. (NASDAQ:VERU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for VERU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for VERU spans 8-K, 10-Q, 424B5, S-3.

Recent high-impact activity:

  • Veru Redirects Sabizabulin to Daraxonrasib-Resistant Pancreatic Cancer After Encouraging Preclinical Results
  • Veru Pivots Sabizabulin to Pancreatic Cancer After Preclinical Win Over Daraxonrasib Resistance
  • Veru Q3 Loss Narrows but Going Concern Warning Persists; Cash Runway Tightens
  • Veru Narrows Q3 Loss, Fully Enrolls Obesity Trial, and Secures Key Patent Allowance
  • Veru's Obesity Trial Fully Enrolled at 239 Patients, Key Patent Allowed

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$22.73M
Op. Cash Flow
-$30.04M
Free Cash Flow
-$30.04M
Operating Income
-$24.75M
Cash & Equivalents
$15.79M
Debt / Equity
0.00×
Shares Outstanding
14.65M sh
Source: 10-K · filed 2025-12-17 · accession 0001437749-25-038089

Short Interest & Short Volume

13.25 days to cover

FINRA reported short interest of 1,499,242 shares in VERU as of the October 30, 2026 settlement, a 2.3% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 19, 2026, 41.0% of VERU volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,499,242 shares as of October 30, 2026
Change vs prior period▲ 2.3%
Days to cover13.25 at avg daily volume of 113,110
Daily short volume (FINRA facilities)41.0% of 24,525 shares on November 19, 2026
5-day average short volume49.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for VERU, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

1 recent capital raiseATM program

At-The-Market Offering Launched · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$2 -4.98% today
52-week range · as of 2026-09-08 $2 – $7.33
Market cap
$34.19M
Volume
211.4K (1.3× avg)
3-mo avg 164K
Live data · 2026-11-20 20:41 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VERU - Latest Insights

VERU
Sep 08, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $2.01 info
Change: -$0.815 (-29%) info
Market Cap: $34.186M info
VERU
Sep 08, 2026, 8:17 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.01 info
Change: -$0.805 (-29%) info
Market Cap: $34.186M info
VERU
Aug 10, 2026, 8:51 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $2.01 info
Change: -$0.445 (-18%) info
Market Cap: $34.186M info
VERU
Aug 10, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.01 info
Change: -$0.4032 (-17%) info
Market Cap: $34.186M info
VERU
Aug 10, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $2.01 info
Change: -$0.285 (-12%) info
Market Cap: $34.186M info
VERU
Jul 27, 2026, 8:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.34
Real-time Price: $2.01 info
Change: -$0.335 (-14%) info
Market Cap: $34.186M info
VERU
Jul 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.97
Real-time Price: $2.01 info
Change: -$0.965 (-32%) info
Market Cap: $34.186M info
VERU
Jul 02, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.97
Real-time Price: $2.01 info
Change: -$0.965 (-32%) info
Market Cap: $34.186M info
VERU
Jul 02, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $3.06
Real-time Price: $2.01 info
Change: -$1.06 (-34%) info
Market Cap: $34.186M info
VERU
Jun 04, 2026, 10:57 PM EDT
Source: dpa-AFX
Importance Score:
9
Price at Filing: $3.77
Real-time Price: $2.01 info
Change: -$1.77 (-47%) info
Market Cap: $34.186M info
VERU
Jun 04, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $2.01 info
Change: -$0.245 (-11%) info
Market Cap: $34.186M info
VERU
May 13, 2026, 9:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $2.01 info
Change: -$0.345 (-15%) info
Market Cap: $34.186M info
VERU
May 13, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.31
Real-time Price: $2.01 info
Change: -$0.305 (-13%) info
Market Cap: $34.186M info
VERU
May 13, 2026, 6:39 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $2.01 info
Change: -$0.285 (-12%) info
Market Cap: $34.186M info
VERU
Apr 07, 2026, 4:18 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $2.46
Real-time Price: $2.01 info
Change: -$0.4503 (-18%) info
Market Cap: $34.186M info
VERU
Mar 13, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.39
Real-time Price: $2.01 info
Change: -$0.385 (-16%) info
Market Cap: $34.186M info
VERU
Mar 09, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.43
Real-time Price: $2.01 info
Change: -$0.425 (-17%) info
Market Cap: $34.186M info
VERU
Feb 11, 2026, 10:32 AM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.44
Real-time Price: $2.01 info
Change: -$0.4349 (-18%) info
Market Cap: $34.186M info
VERU
Feb 11, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $2.01 info
Change: -$0.375 (-16%) info
Market Cap: $34.186M info
VERU
Jan 28, 2026, 4:06 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $2.01 info
Change: -$0.595 (-23%) info
Market Cap: $34.186M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets